Soleno Therapeutics SLNO 深 沪
等待开盘 08-15 09:30:00 美东时间
77.605
-3.535
-4.36%
华盛通- 最 高81.35
- 今 开80.20
- 成交量 108.53万股
- 最 低 77.225
- 昨 收 81.14
- 总市值 40.93亿
- 52周最高 90.3199
- 市盈率 静 --
- 换手率 2.06%
- 52周最低 41.50
- 委 比 47.37%
- 总股本 5274.69万
- 历史最高 90.3199
- 量 比 0.79
- 振 幅 5.08%
- 历史最低 1.81
- 每 手 1
- 风险率 7.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多凯雷Q2继续重仓航空维修巨头StandardAero(SARO.US) 清仓文远知行(WRD.US)
全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2025年6月30日的第二季度持仓报告(13F)。
08-13 18:47
Oppenheimer Maintains Outperform on Soleno Therapeutics, Raises Price Target to $110
Oppenheimer analyst Leland Gershell maintains Soleno Therapeutics (NASDAQ:SLNO) with a Outperform and raises the price target from $105 to $110.
08-07 21:29
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Soleno Therapeutics's Earnings: A Preview
Soleno Therapeutics (NASDAQ:SLNO) is gearing up to announce its quarterly earni...
08-06 01:03
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
Soleno Therapeutics will release its Q2 2025 financial results and hold a conference call on August 6, 2025, at 4:30 PM ET. The call will discuss financials and business updates, with dial-in details and a webcast link provided. The company's drug, VYKAT XR, treats hyperphagia in Prader-Willi syndrome patients, with warnings on hyperglycemia and fluid overload risks. For more info, visit www.soleno.life.
07-28 12:00
Soleno Therapeutics Prices $200M Public Offering Of 2,352,941 Shares At $85/Share
Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced
07-10 21:08
Soleno Therapeutics stock dips on proposed $200M offering
Soleno Therapeutics (NASDAQ:SLNO) shares fell nearly 10% premarket on Thursday after the company proposed an offering of $200 million of shares of its common stock. In addition, the biopharmaceutical ...
07-10 18:24
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Soleno Therapeutics priced its public offering of 2,352,941 shares at $85 per share, raising approximately $200 million. Proceeds will fund the commercialization of VYKAT XR for treating hyperphagia in Prader-Willi syndrome, as well as European market development and R&D.
07-10 13:07
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
Soleno Therapeutics announced preliminary unaudited financial and operational results for Q2 2025. Net revenue from VYKAT XR sales is expected between $31.0 million and $33.0 million. The company had ~$293.8 million in cash, ~646 patient start forms from ~295 prescribers, and ~$50.0 million debt.
07-10 10:00
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
Soleno Therapeutics announced that two abstracts on VYKAT™ XR (diazoxide choline) for treating hyperphagia in Prader-Willi syndrome (PWS) patients will be presented at the Endocrine Society's 2025 Annual Meeting in San Francisco. The studies focus on glycemic outcomes over four years and peripheral edema over 4.5 years. VYKAT XR, approved by the FDA, is the first treatment for hyperphagia in PWS, with safety considerations including hyperglycemia...
07-01 12:00
